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Abstract
Background: Artemisinin and its derivatives have been used for falciparum malaria treatment in
China since late 1970s. Monotherapy and uncontrolled use of artemisinin drugs were common
practices for a long period of time. In vitro tests showed that the susceptibility of Plasmodium
falciparum to artemisinins was declining in China. A concern was raised about the resistance to
artemisinins of falciparum malaria in the country. It has been reported that in vitro artemisinin
resistance was associated with the S769N mutation in the PfATPase6 gene. The main purpose of
this study was to investigate whether that mutation has occurred in field isolates from China.
Methods: Plasmodium falciparum field isolates were collected in 2006–2007 from Hainan and
Yunnan provinces, China. A nested PCR-sequencing assay was developed to analyse the genotype
of the PfATPase6 S769N polymorphism in the P. falciparum field isolates.
Results: The genotyping results of six samples could not be obtained due to failure of PCR
amplification, but no S769N mutation was detected in any of the 95 samples successfully analysed.
Conclusion: The results indicate that the S769N mutation in the PfATPase6 gene is not present in
China, suggesting that artemisinin resistance has not yet developed, but the situation needs to be
watched very attentively.
Background
China has been severely afflicted by falciparum malaria.
In 1954, falciparum malaria cases totaled about 4.18 mil-
lion in the whole country. With active implementation of
malaria control measures for more than 50 years, consid-
erable success has been achieved [1]. However, up to the
present, falciparum malaria is still an important public
health problem in China, especially in Yunnan and
Hainan provinces, with 3,240 cases reported from the two
provinces in 2006, accounting for 93.4% of the total
reported cases in the country [2].
The plant Artemisia annua (Asteraceae) has been used for
more than 2,000 years in Chinese traditional medicine for
the treatment of febrile illnesses, including malaria.
Artemisia annua contains artemisinin, which was isolated
in 1972, and since that time its efficacy against malaria
has been amply demonstrated [3,4]. Following increased
chloroquine (CQ), piperaquine (PQ) and pyrimeth-
amine-sulphadoxine (SP) resistance, artemisinin and its
derivatives gradually became the mainstay of falciparum
malaria therapy in China. Before the World Health Organ-
ization (WHO) urged pharmaceutical companies to end
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the marketing and sale of artemisinin for monotherapy in
2006 [5], many drug manufacturers in China distributed
artemisinin alone to treat malaria; indiscriminate use of
artemisinin derivatives was common practice. Therefore,
whether resistance to artemisinins has developed in China
is a cause for concern.
To this day, clinically relevant artemisinin resistance has
not yet been documented, but it was found that the sus-
ceptibility of Plasmodium falciparum to artemisinin deriva-
tives was declining in China, as IC50 for artesunate in
1999 were 3.3 times of that in 1988 [6]. Laboratory stud-
ies have shown that genetically stable and transmissible
artemisinin-resistant rodent malaria parasite could be
selected through prolonged exposure of drug-sensitive
lines to low and increasing levels of artemisinins [7]. It is
likely a matter of time before clinical artemisinin resist-
ance is observed in China.
Recent studies provide compelling evidences that artem-
isinins act by selectively inhibiting PfATPase6 protein, the
only SERCA-type Ca2+-ATPase in the P. falciparum
genome, believed to be the primary target for artemisinins
[8,9]. A subsequent study in French Guyana showed that
S769N  PfATPase6  mutation was associated with raised
artemether IC50, and suggested that the mutation may be
used in molecular monitoring of artemisinin resistance to
complement continuing in-vitro surveillance [10]. So far,
no studies on this molecular marker have been carried out
in China. The main purpose of the present study was to
investigate whether there are any changes at codon S769N
of the PfATPase6 locus in field samples from the country
following the long-term use of artemisinins. A nested
PCR-sequencing assay was developed to analyse the muta-
tion of PfATPase6 S769N among P. falciparum field iso-
lates collected from Hainan and Yunnan provinces,
China.
Methods
Samples
Plasmodium falciparum field isolates were collected in
2006–2007 from two provinces. 27 samples were col-
lected from Hainan province and 74 samples were from
Yunnan province (Figure 1). The two provinces contrib-
uted more than 90% of the total falciparum malaria cases
in the whole country in 2006 [2]. Parasite samples were
collected from patients with uncomplicated P. falciparum
infections before drug treatment. Diagnosis was carried
out by microscopic examination of Giemsa-stained thick
blood films. For each sample, approximately 20 μL of fin-
ger-prick blood was spotted on a piece of 3 MM filter
paper (Whatman, Maidstone, UK) and air-dried. The
dried filter paper samples were stored in individual zipper
plastic bags with dryer at -20°C until DNA extraction. This
study was reviewed and approved by the ethics committee
of the National Institute of Parasitic Diseases, Chinese
Center for Disease Control and Prevention.
DNA extraction
Extraction of DNA from bloodspots on filter paper was
carried out by the Chelex-100 (Bio-Rad Laboratories, Her-
cules, CA) boiling method described by Wooden and oth-
ers [11] with some modifications described by Pearce and
others [12]. The quality of DNA samples was tested by OD
260/280 measurement.
Nested PCR-sequencing assay
The fragment of pfATPase6 was amplified by nested PCR
with primer F1 (5'-CAAATAAGAAGGATAAATCACCA-3')
and primer R1(5'-TCATAAATACACGTATACCAGCC-3')
(94°C for 3 min; then 94°C for 40 s, 46°C for 1 min, and
72°C for 1 min for 35 cycles; followed by a final extension
step at 72°C for 10 min), and then primer F2 (5'-
AAAATAAATACCACATCAACACAT-3') and primer R2 (5'-
TCAATAATACCTAATCCACCTAAA-3') (94°C for 3 min;
then 94°C for 40 s, 45°C for 1 min, and 72°C for 1 min
for 35 cycles; followed by a final extension step at 72°C
for 10 min). The 50 μL PCR mix contained primers at 0.25
μmol/L final concentration, 2 mmol/L MgCl2, 240 μmol/
L of each deoxynucleoside triphosphate, and 2 U Taq
polymerase. Template DNA (1 μL) was introduced to
outer reaction mixtures. 1 μL outer PCR product was
introduced into a 50 μL inner amplification mixture. Sec-
ondary PCR products were resolved by electrophoresis on
1% agarose gels and visualized by staining with ethidium
bromide. Sequencing reactions were carried out using ABI
PRISM Big Dye terminator v3.1 Cycle Sequencing kit
(Applied Biosystems, CA, USA) as specified by the manu-
facturer's protocol. The sequences of the amplicons were
Map of China showing the locations (shadow) where parasite  samples were collected Figure 1
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aligned with the published data of the NCBI database by
BLAST analysis.
Results
Nested PCR
A 437-base pair fragment in the PfATPase6  gene was
amplified by nested PCR in field samples. Gel electro-
phoresis of the secondary PCR products indicated that
they were of the expected sizes (Figure 2). Under this
amplification conditions, 6 out of 101 samples could not
be amplified.
Sequencing assay
Sequencing assays were successfully performed for the
nested PCR products of 95 samples, no S769N mutation
was detected in any of the analysed samples. Figure 3
shows a sequencing image of nested PCR product, indicat-
ing the polymorphism at codon 769 of the PfATPase6
gene.
Discussion
In this study, by using nested PCR-sequencing assay, no
PfATPase6 S769N mutation was found in any P. falciparum
isolates collected from China. The finding is consistent
with the results from the in vitro microtests [13,14] and
the high (more than 96%) cure rates of artemisinin com-
bination therapies (ACTs) treatment for falciparum
malaria in China [15,16]. Accordingly, until now there is
no sufficient evidence for assuming that artemisinin
resistance has occurred in China. However, stable resist-
ance to artemisinins has been induced in the laboratory,
and the declining susceptibility of P. falciparum to artem-
isinin derivatives has been reported in the country [6].
Artemisinin drugs are believed as the most effective and
the last hope in the near future in the battle against multi-
drug-resistant malaria, if resistance to artemisinins devel-
ops and spreads, it will be the most devastating event in
the history of malaria control [17]. Therefore, it is wise to
phase out artemisinin monotherapy in China; the use of
ACTs recommended by WHO as first line treatment for
uncomplicated malaria will either prevent, or at least
delay, the development of artemisinin resistance.
Although evidences from laboratory and field studies
have suggested that PfATPase6 protein is the primary tar-
get for artemisinins, and a specific S769N mutation in the
gene was significantly associated with the reduced efficacy
of artemisinins [8-10]. It should be pointed out that one
laboratory study could not identify such mutation in
artemisinin-resistant Plasmodium chabaudi [7]. Field stud-
ies carried out in Tanzania and Brazil also could not detect
the S769N PfATPase6 mutation in the analysed samples
[18,19]. Thus, whether this mutation can be widely used
as a reliable marker for artemisinin resistance in epidemi-
ological studies needs further validation.
Conclusion
PfATPase6 S769N mutation was not detected in any of the
P. falciparum isolates from China, no direct evidence sup-
ports that artemisinin resistance has occurred in the coun-
Sequencing image of nested PCR product indicating the polymorphism at codon 769 of the PfATPase6 gene Figure 3
Sequencing image of nested PCR product indicating the polymorphism at codon 769 of the PfATPase6 gene.
Agarose gel electrophoresis of secondary PCR products Figure 2
Agarose gel electrophoresis of secondary PCR prod-
ucts. M, 100 bp DNA ladder. Lanes 1–5, P. falciparum sam-
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try until now. However, a high degree of vigilance is
required; the level of artemisinin sensitivity of P. falci-
parum should be closely monitored.
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